Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance

被引:9
作者
Babrzadeh, Farbod [1 ]
Varghese, Vici [2 ]
Pacold, Mary
Liu, Tommy F.
Nyren, Pal [3 ]
Schiffer, Celia [4 ]
Fessel, W. Jeffrey [5 ]
Shafer, Robert W.
机构
[1] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Div Infect Dis, Dept Med, Stanford, CA 94305 USA
[3] KTH, AlbaNova Univ Ctr, Dept Biotechnol, Stockholm, Sweden
[4] Univ Massachusetts, Med Ctr, Dept Biochem, Worcester, MA USA
[5] Kaiser Permanente Med Care Program No Calif, Clin Trials Unit, San Francisco, CA USA
关键词
drug resistance; deep sequencing; minority variants; Sanger sequencing; ATAZANAVIR;
D O I
10.1093/jac/dks409
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To determine whether pan-protease inhibitor (PI)-resistant virus populations are composed predominantly of viruses with resistance to all PIs or of diverse virus populations with resistance to different subsets of PIs. We performed deep sequencing of plasma virus samples from nine patients with high-level genotypic and/or phenotypic resistance to all licensed PIs. The nine virus samples had a median of 12 PI resistance mutations by direct PCR Sanger sequencing. For each of the nine virus samples, deep sequencing showed that each of the individual viruses within a sample contained nearly all of the mutations detected by Sanger sequencing. Indeed, a median of 94.9 of deep sequence reads had each of the PI resistance mutations present as a single chromatographic peak in the Sanger sequence. A median of 5.0 of reads had all but one of the Sanger mutations that were not part of an electrophoretic mixture. The collinearity of PI resistance mutations in the nine virus samples demonstrated that pan-PI-resistant viruses are able to replicate in vivo despite their highly mutated protease enzymes. We hypothesize that the marked collinearity of PI resistance mutations in pan-PI-resistant virus populations results from the unique requirements for multi-PI resistance and the extensive cross-resistance conferred by many of the accessory PI resistance mutations.
引用
收藏
页码:414 / 418
页数:5
相关论文
共 12 条
  • [1] A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes
    Doherty, Kathleen M.
    Nakka, Priyanka
    King, Bracken M.
    Rhee, Soo-Yon
    Holmes, Susan P.
    Shafer, Robert W.
    Radhakrishnan, Mala L.
    [J]. BMC BIOINFORMATICS, 2011, 12
  • [2] Minority Variants of Drug-Resistant HIV
    Gianella, Sara
    Richman, Douglas D.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (05) : 657 - 666
  • [3] Accuracy and quality of massively parallel DNA pyrosequencing
    Huse, Susan M.
    Huber, Julie A.
    Morrison, Hilary G.
    Sogin, Mitchell L.
    Mark Welch, David
    [J]. GENOME BIOLOGY, 2007, 8 (07)
  • [4] Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID
    Jabara, Cassandra B.
    Jones, Corbin D.
    Roach, Jeffrey
    Anderson, Jeffrey A.
    Swanstrom, Ronald
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (50) : 20166 - 20171
  • [5] A survey of sequence alignment algorithms for next-generation sequencing
    Li, Heng
    Homer, Nils
    [J]. BRIEFINGS IN BIOINFORMATICS, 2010, 11 (05) : 473 - 483
  • [6] HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
    Rhee, Soo-Yon
    Taylor, Jonathan
    Fessel, W. Jeffrey
    Kaufman, David
    Towner, William
    Troia, Paolo
    Ruane, Peter
    Hellinger, James
    Shirvani, Vivian
    Zolopa, Andrew
    Shafer, Robert W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (10) : 4253 - 4261
  • [7] Human immunodeficiency virus reverse transcriptase and protease sequence database
    Rhee, SY
    Gonzales, MJ
    Kantor, R
    Betts, BJ
    Ravela, J
    Shafer, RW
    [J]. NUCLEIC ACIDS RESEARCH, 2003, 31 (01) : 298 - 303
  • [8] Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations
    Shahriar, Rajin
    Rhee, Soo-Yon
    Liu, Tommy F.
    Fessel, W. Jeffrey
    Scarsella, Anthony
    Towner, William
    Holmes, Susan P.
    Zolopa, Andrew R.
    Shafer, Robert W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) : 4869 - 4878
  • [9] Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
    Talbot, Annie
    Grant, Philip
    Taylor, Jonathan
    Baril, Jean-Guy
    Liu, Tommy Fulisma
    Charest, Hugues
    Brenner, Bluma
    Roger, Michel
    Shafer, Robert
    Cantin, Regis
    Zolopa, Andrew
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2473 - 2479
  • [10] Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones
    Weinheimer, S
    Discotto, L
    Friborg, J
    Yang, H
    Colonno, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3816 - 3824